Search Database

Name

Erwinaze

Alternate Names

Asparaginase erwinia chrysanthemi

Abbreviations

None

Category

Chemotherapy

Subcategory

Antineoplastic agent

NSC Number

None

Primary Site

Acute lymphoblastic leukemia (ALL)

Histology

None

Remarks

Erwinaze received FDA approval November 2011 for the treatment of acute lymphoblastic leukemia (ALL). The FDA has designated Erwinaze as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S. It is manufactured by EUSA Pharmaceutical.

Coding

This drug should be coded
Glossary